Drug Profile
Pegsunercept
Alternative Names: PEG sTNF-R1; PEG sTNF-RI; Pegylated recombinant methionyl human soluble tumour necrosis factor receptor type 1; Pegylated soluble tumour necrosis factor receptor type ILatest Information Update: 23 Sep 2021
Price :
$50
*
At a glance
- Originator Amgen
- Class Anti-inflammatories; Antirheumatics
- Mechanism of Action Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 03 Aug 2006 No development reported - Phase-II for Rheumatoid arthritis (unspecified route)
- 03 Aug 2006 No development reported - Phase-II for Rheumatoid arthritis in USA (unspecified route)
- 31 Dec 2003 Amgen has completed a Phase-II trial in Rheumatoid arthritis in the USA